Sun Pharma deal
Sun Pharma on Monday announced the largest acquisition by any Indian pharmaceutical company so far. The company acquired US-listed Organon & Co. Has agreed to buy. This is a completely cash deal, whose enterprise value is $ 11.75 billion, which is more than Rs 1 lakh crore as per the current currency exchange rate. This move will dramatically change Sun Pharma’s global scale and therapeutic scope. In this deal, the valuation of Organon has been done at $ 14 per share in cash. This is a decisive step in Sun Pharma’s strategy to rapidly transform itself into a large, diversified global medicine maker and explore new avenues of growth beyond traditional generic medicines.
Business is spread in 140 countries
The acquisition aims to strengthen Sun Pharma’s presence in women’s health, established brands and biosimilar medicines, as well as significantly expand its commercial reach in advanced markets. Organon brings with it a strong global identity. Its business is spread in more than 140 countries. The company has a very strong position in the field of contraception and fertility. It has a large portfolio of over 50 established brands, and its biosimilar business is growing rapidly.
For Sun Pharma, the deal adds women’s health as a new pillar of innovation along with dermatology, ophthalmology and onco-dermatology. Additionally, it gives it immediate exposure to the field of biosimilar drugs, where Organon is already one of the top companies in the world.
Revenue will double
From a financial point of view, this acquisition represents a big step-change. After the merger, the joint unit of Sun and Organon is expected to generate annual revenue of $12.4 billion. This will almost double Sun Pharma’s stand-alone revenue of $6.2 billion in FY2025, and the combined EBITDA will increase to about $3.7 billion. The merged company will derive a major portion of its revenue from new drugs and branded products. This will reduce reliance on commoditized generic drugs, and create a more balanced business mix between innovation, established brands and biosimilar drugs.
Where will the funding come from?
Sun Pharma has said that this deal will be funded in two ways. Which includes 22.5 billion cash present in the balance sheet of the company and a secured loan of 9.259.75 billion dollars received from banks. Despite the large size of the acquisition, the management expects the company’s debt burden (leverage) to remain under control. Backed by Organon’s strong and predictable cash flows, the net debt-to-EBITDA ratio on a combined basis is expected to be approximately 1.8x. Organon generates more than $1 billion of annual free cash flow before the financing, which Sun plans to use to rapidly reduce debt, while also continuing to invest in research, development and future business development opportunities.
Where and how will you earn?
Management has presented the Organon deal as a transformative opportunity rather than just a financial transaction. This integration is expected to provide potential synergy of more than $350 million within two to four years. This will be due to cost reduction, supply-chain optimization and SunPharma’s strategy to implement branded-generics on Organon’s well-known brands. Sun Pharma also expects to gain significantly from the integration of products into different markets and from licensing new therapies to scale them up using Organon’s strong global commercial network.
When Ranbaxy was bought
This acquisition builds on Sun Pharma’s long history of large and complex transactions. The most notable among these is the acquisition of Ranbaxy in 2014, as well as several special licensing deals that strengthened the company’s portfolio of new and innovative medicines. Over the last decade and a half, these steps have led to a 14.4 per cent annual growth rate in the company’s revenue and a CAGR of 13 per cent in EBITDA between FY 2010 and FY 2025. This has further strengthened their confidence in management’s ability to integrate large businesses and extract benefits from them over time.
Revenue of more than 100 million from 18 countries
Once this process is complete—which is expected in early 2027 after receiving shareholder and regulatory approvals—the newly formed company will have a presence in all major pharmaceutical markets. This will include 18 countries that will generate revenues of more than $100 million each, and the company will have a global commercial team of approximately 24,000 people. This expanded platform will enable Sun Pharma to emerge as a stronger partner for global licensing deals.
